sibutramine has been researched along with Asystole in 1 studies
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride
| Excerpt | Relevance | Reference |
|---|---|---|
| "A previously well 51-year-old woman with obesity but no other relevant past medical history or cardiac risk factors was prescribed sibutramine (initial dose 10 mg daily, increased to 15 mg daily after 10 wk)." | 3.74 | Sibutramine-associated QT interval prolongation and cardiac arrest. ( Corallo, CE; Ernest, D; Gershenzon, A; Nagappan, R, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ernest, D | 1 |
| Gershenzon, A | 1 |
| Corallo, CE | 1 |
| Nagappan, R | 1 |
1 other study available for sibutramine and Asystole
| Article | Year |
|---|---|
Sibutramine-associated QT interval prolongation and cardiac arrest.
Topics: Appetite Depressants; Cyclobutanes; Defibrillators, Implantable; Drug Monitoring; Electrocardiograph | 2008 |